BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma
Daratumumab Plus RVd as Induction Therapy Improves Responses, Survival in Newly Diagnosed Myeloma
Mezigdomide Plus Tazemetostat and Dexamethasone Is Effective and Safe in Refractory Myeloma
Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma